Table 3.
Multivariate analysis of factors associated with the chance of breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC)
| OR | 95 % CI | |
|---|---|---|
| Histology | ||
| ILC | 1 | |
| IDC | 1.91 | 1.49–2.44 |
| Clinical tumor size | ||
| T1 | 1 | |
| T2 | 1.25 | 1.01–1.54 |
| T3 | 0.23 | 0.18–0.30 |
| T4 | 0.07 | 0.04–0.10 |
| Age (years) | ||
| <50 | 1 | |
| 50–70 | 1.35 | 1.17–1.56 |
| >70 | 0.59 | 0.34–1.02 |
| Estrogen receptor status | ||
| Negative | 1 | |
| Positive | 0.84 | 0.68–1.04 |
| Progesterone receptor status | ||
| Negative | 1 | |
| Positive | 1.11 | 0.92–1.35 |
| HER2 receptor status | ||
| Negative | 1 | |
| Positive | 0.95 | 0.81–1.13 |
OR odds ratio, CI confidence interval, ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, HER human epidermal growth factor receptor